Congress mandates free prostate screening for high-risk men, targeting health disparities
S. 297 — PSA Screening for HIM Act · Filed by John Boozman (R-AR) · 6 cosponsors · Introduced Jan 29, 2025 · Hearing held
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires health insurance plans to cover prostate cancer screening without cost-sharing (copays, deductibles) for men age 40+ who are at high risk—specifically African-American men and men with a family history of prostate cancer. The bill cites disparities in prostate cancer diagnosis and mortality, particularly among African-American men, and aims to remove financial barriers to early detection.
Why we flagged it
The bill's core function is to mandate insurance coverage of prostate cancer screening for a defined high-risk population without cost-sharing. It is a public health measure, not a market intervention or corporate benefit.
What the text implies
- The bill defines 'high-risk' narrowly (African-American men and family history), which may exclude other at-risk populations and could create a two-tier screening landscape where some men receive covered screening and others do not.
- The effective date (January 1, 2025) is retroactive to the bill's introduction, suggesting intent for immediate implementation if passed, which may create administrative burden for insurers mid-year.
The full analysis lists 3 implications of this text.
Who stands to gain
health insurance issuers (may face increased claims costs); diagnostic testing companies (PSA test providers); urology and oncology practices